23rd Congress of the European Hematology Association Stockholm, Sweden, June 14‐17, 2018
, 2018 HemaSphere, Volume 2, Issue S1, Page 1-1113, June 2018.
wiley +1 more source
CHRONIC MYELOGENOUS LEUKEMIA: A REVIEW AND UPDATE OF CURRENT AND FUTURE THERAPY [PDF]
, 2016 Leukemia is a cancer of marrow and blood, which is a clonal myeloproliferative disease, characterized by the presence of oncogenic Philadelphia chromosome, formed by a reciprocal translocation between chromosomes 9 and 22, resulting in the novel chimeric
Bharadia, Praful D +1 more
core +1 more source
Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia. [PDF]
Int J Mol Sci, 2023 Lahlil R +5 more
europepmc +1 more source
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. [PDF]
J Pharmacokinet Pharmacodyn, 2023 Ruiz-Garcia A +14 more
europepmc +1 more source
Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. [PDF]
Cell Rep Med, 2023 Liu C +11 more
europepmc +1 more source
Pleural effusion in hematological pathology. [PDF]
Cytojournal, 2021 Yerrapotu N +3 more
europepmc +1 more source
Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein
Haematologica, 2019 Haruka Shinohara +3 more
doaj +1 more source
Investigating the SRC kinase HCK functions in Chronic Myelogenous Leukemia using chemical genetics methods. [PDF]
, 2009 The hallmark of chronic myelogenous leukemia (CML) is a chromosomal translocation between the c-abl gene (chromosome 9) and the bcr gene (chromosome 22).
Pene Dumitrescu, Teodora
core +1 more source
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. [PDF]
Front Physiol, 2021 Santoro M +5 more
europepmc +1 more source